Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | MGA271 |
Trade Name | |
Synonyms | Enoblituzumab |
Drug Descriptions |
MGA271 (enoblituzumab) is an inhibitory monoclonal antibody against CD276 (B7-H3), which induces an anti-tumor immune response (PMID: 22615450). |
DrugClasses | CD276 Antibody 16 |
CAS Registry Number | 1353485-38-7 |
NCIT ID | C97510 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Aldesleukin + FT516 + MGA271 | Aldesleukin FT516 MGA271 | 0 | 1 |
FT538 + MGA271 | FT538 MGA271 | 0 | 1 |
Ipilimumab + MGA271 | Ipilimumab MGA271 | 0 | 1 |
MGA271 | MGA271 | 0 | 4 |
MGA271 + MGD013 | MGA271 MGD013 | 0 | 1 |
MGA271 + Pembrolizumab | MGA271 Pembrolizumab | 0 | 1 |
MGA271 + Retifanlimab | MGA271 Retifanlimab | 0 | 1 |